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Abstract
Isolated hypocortisolism due to ACTH deficiency is a rare condition that can be caused by homozygous or
compound heterozygous mutations in the gene encoding proopiomelanocortin (POMC). Loss of function
mutations of POMC gene typically results in adrenal insufficiency, obesity and red hair. We describe an 18 month
old Hispanic female with congenital adrenal insufficiency, a novel POMC mutation and atypical clinical features. The
patient presented at the age of 9 months with hypoglycemia and the endocrine evaluation resulted in a diagnosis
of ACTH deficiency. She developed extreme weight gain prompting sequence analysis of POMC, which revealed a
homozygous c.231C > A change which is predicted to result in a premature termination codon. The case we
report had obesity, hypocortisolism but lacked red hair which is typical for subjects with POMC mutations.
Mutations of POMC should be considered in individuals with severe early onset obesity and adrenal insufficiency
even when they lack the typical pigmentary phenotype.
Introduction
Congenital isolated ACTH deficiency is a rare condition. It
is characterized by decreased plasma adrenocorticotropic
hormone (ACTH) concentration resulting in adrenal
insufficiency and consequently low serum cortisol concen-
tration and lack of hyperpigmentation. These subjects
show no ACTH response to exogenous corticotrophin
releasing hormone (CRH) administration and have a nor-
mal pituitary morphology. Additionally, the other pituitary
hormones are normal, unlike secondary adrenal insuffi-
ciency which can be associated with multiple pituitary hor-
mone deficiencies. Congenital isolated ACTH deficiency
may present in early neonatal period or in later childhood.
ACTH is produced from the precursor molecule proo-
piomelanocortin (POMC), by the action of the cleavage
hormone pro-hormone convertase 1 (PCSK1) when sti-
mulated by CRH. The genes associated with congenital
isolated ACTH deficiency are TBX19 (TPIT), PCSK1
(PC1)a n dPOMC. Genetic mutations in CRH or its
receptor have not been associated with isolated ACTH
deficiency [1]. TBX19 is a cell restricted transcription fac-
tor required for terminal differentiation of pituitary
corticotrophs and for expression of POMC. Typically,
individuals with TBX19 mutations present with neonatal
hypoglycemia and cholestatic jaundice and account for
73% of isolated ATCH deficiency [2]. PCSK1 (PC1) muta-
tions are rare and have been described in two cases with
obesity, abnormal glucose homeostasis, ACTH and gona-
dotropin deficiency and gastrointestinal abnormalities
[3]. The classical clinical triad described with POMC
mutations includes early onset obesity, hypocortisolism
and red hair.
We describe an individual with early onset obesity,
adrenal insufficiency and a novel POMC mutation but
without the typical pigmentary phenotype of red hair
and pale skin.
Case Report
A 9 month old female presented with hypoglycemia and
hyponatremia following a three day history of fever,
emesis, poor oral intake and progressive lethargy. She was
the first born child of nonconsanguinous parents of Hispa-
nic ethnicity whose family history was noncontributory.
Both parents were of average build (father’s BMI 25.8 and
mother’s 24.5). Mother received routine prenatal care and
there were no complications during the pregnancy. She
was born appropriate for gestational age at 38 weeks via
spontaneous vaginal delivery and was in the hospital for a
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was also significant for delayed motor milestones. She
could not sit without support, nor did she crawl or roll
over but had a pincer grasp.
On the day of presentation, she became increasingly
lethargic and was taken to a hospital where she was
found to be hypoglycemic (blood glucose 1.2 mmol/L)
and hyponatremic (Na 121 mmol/L). Her weight was
11.5 kg, head circumference 47 cm (both above the 95th
percentile) while her length was 72 cm (at the 75
th per-
centile). Craniofacial features were notable for dark hair
and dark roots, broad forehead with mild frontal bos-
sing. Head and neck examination revealed a right sided
otitis media and fundoscopy was normal with no signs
of optic atrophy. Skin examination showed no hyperpig-
mentation of nipples or palmer creases. The remainder
of her physical examination was normal. She was stabi-
lized on intravenous fluids. Both her blood glucose and
sodium levels normalized. Urinalysis and culture were
diagnostic of a urinary tract infection. Two days after
admission, she developed a right sided pleural effusion
and moderate ascites. As her condition worsened, she
required intubation and intensive care. A random corti-
sol level was low prompting a 1 mcg ACTH stimulation
test which revealed no response with a low ACTH level.
Thyroid function studies and growth factors were nor-
mal (Table 1). MRI of the brain revealed a normal pitui-
tary morphology.
Secondary adrenal insufficiency was clinically suspected
due to the lack of hyper-pigmentation. As primary adre-
nal insufficiency was not under consideration, renin and
aldosterone levels were not obtained. Hyponatremia may
be seen in severe cortisol deficiency due to decreased free
water clearance. Congenital isolated ACTH deficiency
was diagnosed based on her clinical presentation, absent
hyperpigmentation, low basal and stimulated cortisol
levels and normal levels of other pituitary hormones.
Exon sequencing of TBX19 was normal. She recovered
with stress dose steroids and intravenous antibiotics and
was discharged on oral maintenance glucocorticoid repla-
cement with hydrocortisone (10 mg/m
2/day) and blood
glucose monitoring.
During follow up, the mother was concerned about
the child’s increased appetite and weight gain (Figure 1)
and reported normal blood glucose levels at home.
Although the patient did not have red hair, gene
sequencing of POMC was performed due to her obesity
and adrenal insufficiency. POMC gene sequencing
showed a homozygous c.231C > A change which causes
a premature termination codon. Each parent was hetero-
zygous for this mutation (Figure 2).
Discussion
Individuals with adrenal insufficiency usually present
with weight loss, fatigue, hypoglycemia, severe infections
and shock. Our subject was diagnosed with adrenal insuf-
ficiency due to isolated ACTH deficiency, based on her
clinical presentation and endocrinology evaluation. She
was obese on initial examination and continued to gain
weight. Iatrogenic hypercortisolism as a cause of her
abnormal weight gain was not suspected as her linear
growth did not deviate from her established percentile
curve (Figure 1) and she received normal maintenance
steroid dose. The diagnosis of POMC deficiency was con-
firmed by exon sequencing of the POMC gene which
showed a novel homozygous mutation. This mutation
caused a substitution of cytosine by adenosine at codon
231 resulting in a premature stop codon instead of tyro-
sine at amino acid position 77 (p.Y77X).
POMC is a complex pro-peptide, encoded on chromo-
some 2p23.3. It is expressed in several tissues including
the hypothalamus, pituitary gland, skin and the immune
system [4]. POMC is processed post-translationally to pro-
duce the bioactive peptides: ACTH, b-endorphin, and a-,
b-, g- melanocyte stimulating hormones (MSH) (Figure 3).
The action of these melanocortins is mediated through
the action of five melanocortin receptors: MC1R to
MC5R. MC1R, MC2R and MC5R have been implicated in
pigmentation of the skin, adrenal steroidogenesis and ther-
moregulation respectively [5]. MC3R and MC4R are
expressed in the lateral hypothalamic, hypothalamic parvi-
cellular and perifornical areas and play an important role
in food intake and energy expenditure [3]. The action of
ACTH is well recognized and it is the only known ligand
of MC-2R. a-MSH binds to MC1R in melanocytes to sti-
mulate the synthesis of eumelanin (black/brown pigment)
[6] and is involved in the control of food intake and energy
expenditure through MC3 and MC4 receptors [7]. There
is evidence that b- MSH also plays a role in the control of
human energy homeostasis [8]. g-MSH has been impli-
cated in the central control of the cardiovascular system
while b-endorphin plays a role in pain perception and
analgesia [9].
The first two cases of POMC deficiency were
described by Krude et al., in 1998 [10]. These two sub-
jects of Caucasian descent presented with hypoglycemia
Table 1 Laboratory evaluation
Analyte Patient Value Normal range for age
Random Cortisol nmol/L 19.31 77.25-634
Stimulated Cortisol nmol/L 27.29 > 496.6
ACTH pmol/L < 1.1 1.1-5.94
TSH mU/L 3.6 0.32-5
T4 nmol/L 97.81 89.6-193
IGF-1 mcg/L 46.l 25- 265
IGF-BP3 mg/L 1.8 0.7-3.6
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ATCH deficiency which was associated with early onset
obesity and red hair [10]. Three more individuals
d e s c r i b e db yt h es a m eg r o u pi n2 0 0 3h a das i m i l a r
clinical phenotype [11]. However, Farooqi in 2006
described a two year male of Turkish ethnicity with cen-
tral hypocortisolism, severe obesity at 6 months and
dark colored hair [12]. On closer inspection, they noted
 
 
 
 
Hydrocortisone Treatment 
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Figure 1 Patient (age 30 months) and her growth chart.
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old female of North African ancestry with ACTH defi-
ciency at birth, severe early onset obesity and dark hair
was described by Clément in 2008 [13]. At the age of 13
years, she had delayed puberty and on evaluation was
found to have hypothyroidism, hypogonadism and
growth hormone deficiency (Table 2).
POMC knockout (POMC
-/-) mice models show a simi-
lar phenotype with adrenal insufficiency, marked obesity
and altered pigmentation. These POMC
-/- mice also
have higher fat mass than age-matched normal wildtype
(WT) mice and a reduced basal metabolic rate. Their
total plasma T4 levels were significantly lower than
those of WT mice. Thus, the obesity phenotype may be
A
              
                
B
   Wildtype                                  Homozygous c.231C>A (p.Y77X)               Heterozygous c.231C>A (p.Y77X)
c.231C>A (p.Y77X)/+
c.231C>A (p.Y77X)/c.231C>A (p.Y77X)
c.231C>A (p.Y77X)/+
Figure 2 Patient pedigree and POMC gene mutation analysis. (A) Pedigree of the nuclear family with mutation status noted. (B) Sequence
chromatograms: wildtype sequence (left) with a C at nucleotide position 231 of the POMC gene, patient (middle) with homozygous substitution
of A for C resulting in tyrosine at amino acid position 77 (p.Y77x), a premature stop codon and parental sequence (right) demonstrates
heterozygote C to A substitution represented by the letter M (arrow).
-MSH                 -MSH  CLIP                      -MSH    -Endorphin
c.231C>A (p.Y77X)                   ACTH                           -Lipotropin
-Lipotropin
Figure 3 Proopiomelanocortin protein. The POMC gene encodes a hormone precursor for distinct melanotropins (MSH), lipotropins, and
endorphins including -MSH (amino acids 77-87, shown in light blue), -MSH (amino acids 138-150, shown in green), Corticotropin-like
intermediary peptide (CLIP) (amino acids 156-176, shown in yellow), ACTH (amino acids 138-176, in brackets), -MSH (amino acids 217-234, shown
in orange), -endorphin (amino acids 237-267, shown in blue), -Lipotropin (amino acids 179-267, in brackets), and Lipotropin (amino acids 179-
234, in brackets). The amino acid positions are not drawn to scale. The c.231C>A mutation causes a premature stop within the protein just
upstream of the MSH motif.
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[3]. Administration of a-MSH ameliorated the obesity
seen in these mice [7]. Coll’s group also demonstrated
that POMC heterozygous mice (POMC
+/-) had a weight
similar to WT mice on standard chow but became
obese on high fat chow (45% fat) due to increased food
intake [3]. In humans, genetic linkage studies have iden-
tified chromosome 2p22 (region encompassing the
POMC gene) as the site of gene or genes influencing
common obesity [14]. Heterozygous mutations in MC4R
are the commonest known cause of monogenic obesity
[3]. Farooqi’s group studied the other family members
of the Turkish child and found that 11 of the 12 who
were heterozygote POMC carriers were obese as com-
pared to the one of 7 wild type family members [12].
This strongly suggests that the loss of one copy (hap-
loinsufficiency) of the POMC gene predisposes to obe-
sity [6]. Various point mutations of the POMC gene
have also been shown to increase the risk of obesity in
carriers [8,15].
The management of obesity in POMC deficiency
remains a challenge. Krude’s group administered intra-
nasal ACTH 4-10 to the first two probands in a 3 month
trial period [11]. The peptide fragment ACTH 4-10 is iden-
tical to a-MSH and was shown to be effective in reducing
body weight in normal weight individuals [16]. However,
even with the maximum dose of 5 mg/day, there was no
effect on weight, body composition or metabolic rate. This
lack of activity was explained by the lower affinity of
ACTH 4-10 to MC4R. These two subjects also had
repeated elevation of TSH, borderline reduction of total
T4 and normal T3 levels. Both were treated with levothyr-
oxine for a year to normalize T4 and TSH, but again this
had no impact on their weight [11].
Melanocortin peptides stimulate both melanogenesis
and the switch from pheo (red-yellow) to eumelanogenic
(black) pathways [17]. The 18 year old North African
subject underwent hair pigment analysis which showed a
significant increase in the levels of both eumelanin and
pheomelanin. However, there was a reduced ratio of
eumelanin to pheomelanin [13]. In mice, POMC inactiva-
tion causes a lighter coat on some genetic backgrounds.
However, Slominski and his group showed that non-
agouti 129;B6 mice with POMC deletion, showed normal
eumelanin production with no effect on hair color. They
speculated that this may be due to ligand independent
activity of MC1R which allows synthesis of eumelanin
[17]. Similarly, in Caucasians, eumelanin synthesis is
more dependent on the presence of POMC derived pep-
tides while in non-Caucasian ethnic groups, other genetic
variants may act to maintain eumelanin synthesis [18].
The individual we present is an 18 month old female of
Hispanic ethnicity, with POMC deficiency associated
with hypocortisolism and early onset obesity, but without
the typical phenotype of red hair. She has dark brown-
black hair and roots. On closer questioning, the mother
stated that her daughter’sh a i ra n dh a i rr o o t sh a v e
remained unchanged since birth but noted that it has a
reddish glint in sunlight. However, we were not able to
appreciate this in the fluorescent lighting of the examina-
tion room. She has a novel POMC gene mutation which
may allow expression of hair color or as discussed above,
hair pigmentation in non-Caucasians may not be entirely
dependent on melanocortin peptides. Since POMC
derived peptides have a wide array of biological functions,
it is possible that she may develop other manifestations
later on in life. In conclusion, POMC gene mutations
should be considered in patients with early onset severe
obesity, adrenal insufficiency even in the absence of red
hair, especially in non-Caucasians.
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Table 2 Previously reported cases of POMC deficiency
Age/Gender Country/region of origin Triad criteria
(red hair, AI, obesity)
POMC gene mutation Reference
Neonatal/M Slovenia + A6851T/6996del Krude[11]
4 weeks/M Netherlands + C3804A/C3804A Krude[11]
6 months/F Switzerland + C3804A/7100insGG Krude[11]
2 years/M Turkey - C6906del/C6906del Farooqi[12]
3 years/F Germany + G7013T/C7133del Krude[10]
5 years/M Germany + C3804A/C3804A Krude[10]
18 years/F North Africa - 6922insC/6922insC Clément[13]
Unknown Japan unknown GTG3895AC Krude[9]
* AI = adrenal insufficiency
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